Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.
Cancer biotech Intensity Therapeutics looks to pull in $16M+ IPO
Cancer biotech Intensity Therapeutics launched an IPO as it aims to advance a therapy being tested in sarcoma and breast cancer. The Connecticut biotech announced